Remibrutinib

Rhapsido

25 MG TabletCanadaAuthorised

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Rhapsido 25 MG Comprimidos Recubiertos con PeliculaSpain · 25 mg · comprimido recubierto con película · Novartis Europharm LimitedSame brand
RhapsidoEuropean Union · Novartis Europharm LimitedSame brand
RhapsidoCroatiaSame brand
RhapsidoItaly · Compressa rivestita con film · Novartis Europharm LimitedSame brand
Rhapsido 25 mg filmomhulde tablettenNetherlands · Filmomhulde tablet · Novartis Europharm LimitedSame brand
RhapsidoUnited States · 25MG · tablet · NovartisSame brand

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Remibrutinib

Rhapsido

25 MG TabletCanadaAuthorised

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Remibrutinib
Strength: 25 MG
Dosage form: Tablet
Route: Oral
Register: Canada (Health Canada)
Status: Authorised
Status in the register: Approved
Registration: DIN 02570076
Marketing authorisation holder: Novartis Pharmaceuticals Canada INC
ATC code: L04AA60
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION